Day 1. Friday, 26 September 2025,

1.30pm to 8.30pm

Time

Title

Speakers

12.30pm to 1.30pm

Registration

1.30pm to 1.50 pm

Welcome and Opening Remarks

Dr. Mohamed Salem Al-Hassan

CEO & Medical Director, NCCCR. Chairman, Corporate Cancer Services, HMC

Sheikh Dr. Khalid bin Jabor Al Thani

Chairman of Qatar Cancer Society

Dr. Mohammed Ussama Al-Homsi

Conference Chairman

Deputy Medical Director for Research and Medical Education, Senior Consultant Medical Oncologist, NCCCR

Dr. Robin Zon

ASCO President

Session 1 - Moderators: Dr. Kakil Rasul, Dr. Shouki Bazarbashi

1.50pm to 2.05pm

Gastrointestinal Cancer - Colorectal and Anal (Abstract 3513) FIRE-4 (AIO KRK-0114): Randomized study evaluating the efficacy of cetuximab re-challenge in patients with metastatic RAS wild-type colorectal cancer responding to first-line treatment with FOLFIRI plus cetuximab

Dr. Shouki Bazarbashi

Consultant Medical Oncologist, Cancer center of excellence, King Faisal Specialist Hospital & Research Centre, KSA

2.05pm to 2.20pm

Gastrointestinal Cancer - Colorectal and Anal (Abstract 3501) Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded analyses from CheckMate 8HW

Dr. Kakil Rasul

Senior Consultant Medical Oncologist, NCCCR

2.20pm to 2.35pm

Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary (Abstract LBA4002) Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study

Dr. Mohamed Sir Elkhatim Hamid

Consultant Medical Oncologist, NCCCR

2.35pm to 2.50pm

Gastrointestinal Cancer - Colorectal and Anal (Abstract LBA1) Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)

Dr. Mai Mostafa

Consultant Medical Oncologist, NCCCR

2.50pm to 3.05pm

Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary (Abstract 4000) Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577

Dr. Ahmed Abdalhadi

Clinical Fellow, Oncologist, NCCCR

3.05pm to 3.20pm

PANEL DISCUSSION

3.20pm to 3.40pm

Prayer & Coffee Break

Session 2 - Moderators: Dr. Alaaeldin Shablak, Dr. Kannan AlShummari

3.40pm to 3.55pm

Gastrointestinal Cancer - Colorectal and Anal (Abstract 3505) Perioperative systemic therapy for resectable colorectal peritoneal metastases: A multicenter randomized phase 3 trial (CAIRO6)

Dr. Kannan AlShummari

Consultant Medical Oncologist, King Abdulaziz Medical City, KSA

3.55pm to 4.10pm

Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary (Abstract LBA5) Event-free survival in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC)

Dr. Alaaeldin Shablak

Consultant Medical Oncologist, NCCCR

4.10pm to 4.25pm

Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary (Abstract LBA4005) PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC)

Dr. Wamda Abdalla

Associate Consultant Medical Oncologist, NCCCR

4.25pm to 4.40pm

Gastrointestinal Cancer - Colorectal and Anal (Abstract LBA3500) First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): progression-free survival and updated overall survival analyses

Dr. Aleem Akram

Associate Consultant, Medical Oncologist, NCCCR

4.40pm to 4.55pm

Gastrointestinal Cancer - Colorectal and Anal (Abstract LBA3510) A randomized phase III trial of the impact of a structured exercise program on disease–free survival (DFS) in stage 3 or high-risk stage 2 colon cancer: Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE)

Dr. Meeloud Aldardouri

Specialist, Oncologist, NCCCR

4.55pm to 5.10pm

Central Nervous System Tumors (Abstract 2011) Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial

Dr. Mohamed Riyas

Senior Consultant Radiation Oncologist, NCCCR

5.10pm to 5.25pm

PANEL DISCUSSION

5.25pm to 5.45pm

Prayer & Coffee Break

Session 3 - Moderators: Dr. Salha Bujassoum, Dr. Mufid El Mistiri, Dr. Suad Al-Kharousi

5.45pm to 6pm

Breast Cancer - Local/Regional/Adjuvant (Abstract 505) 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS

Dr. Suad Al-Kharousi

Director of the National Center for Oncology at the Royal Hospital, Oman

6pm to 6.15pm

Breast Cancer - Local/Regional/Adjuvant (Abstract 507) The impact of ovarian function suppression with adjuvant endocrine therapy on survival outcomes in young germline BRCA mutation carriers with breast cancer: Secondary analysis of an international cohort study

Dr. Maha Al Sindi

Medical Oncologist, Bahrain Oncology Centre, Bahrain

6.15pm to 6.30pm

Breast Cancer - Metastatic (Abstract LBA4) Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial

Dr. Salha Bujassoum

Chair of Medical Oncology and Palliative Care, Senior Consultant Medical Oncologist, NCCCR

6.30pm to 6.45pm

Breast Cancer - Metastatic (Abstract LBA1008) Trastuzumab deruxtecan (T-DXd) ± pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Primary results from DESTINY-Breast09

Dr. Mufid El Mistiri

Senior Consultant Medical Oncologist, NCCCR

6.45pm to 7pm

Breast Cancer - Metastatic (Abstract LBA109) Sacituzumab govitecan (SG) + pembrolizumab vs chemotherapy + pembrolizumab in patients with previously untreated PD-L1+ advanced or metastatic triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study

Dr. Francois Calaud

Senior Consultant Medical Oncologist, NCCCR

7pm to 7.15pm

Breast Cancer - Metastatic (Abstract LBA1000) Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study

Dr. Ahlam Yousif

Consultant Medical Oncologist, NCCCR

7.15pm to 7.30pm

Breast Cancer - Local/Regional/Adjuvant (Abstract LBA500) De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial

Dr. Mohammed Gaber

Associate Consultant, Medical Oncologist, NCCCR

7.30pm to 7.45pm

Breast Cancer - Local/Regional/Adjuvant (Abstract 1003) INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC)

Dr. Shaza Bek

Associate Consultant, Medical Oncologist, NCCCR

7.45pm to 8pm

Breast Cancer - Local/Regional/Adjuvant (Abstract 508) Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy: Phase 3 OASIS 4 trial

Dr. Shaima Abdelrahim

Clinical Fellow, Oncologist, NCCCR

8pm to 8.15pm

PANEL DISCUSSION

8.15pm to 8.30pm

Day1 Closing Remarks

8.30pm

Dinner